tumor necrosis factor

Type: Keyphrase
Name: tumor necrosis factor
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

TNF antagonists not linked with cancer in Danish study

The use of tumour necrosis factor alpha (TNF-α) antagonists to treat inflammatory bowel disease (IBD) is not associated with an increased risk of cancer, analysis of a Danish registry indicates1.The analysis, conducted by researchers from State...Related ... [Published BioPortfolio - Jul 09 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Tumor necrosis factor inhibitors

The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated ... [Published Free Patents Online - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

Albany, NY -- (SBWIRE) -- 07/01/2014 -- Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are ... [Published SearchBug - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Protective Effect of Ginkgo biloba leaves extract, EGb761, on Endotoxin-Induced Acute Lung Injury via a JNK- and Akt-Dependent NFκB Pathway

Acute lung injury (ALI) is a clinical syndrome mainly caused by Gram-negative bacteria which is still in need of an effective therapeutic medicine. EGb761, an extract of Ginkgo biloba leaves, has several bioeffects including anti-inflammation, cardioprotection, ... [Published Journal of Agricultural and Food Chemistry - Jul 01 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Chemokine binding activity of viral TNF receptors and related proteins

. The invention relates to a C-terminal domain (CTD) of viral tumor necrosis factor receptors (vTNFRs) CrmB or CrmD or CTD homologues (CTD1, CTD2 and CTD3) from poxvirus and their functional homologues, including derivatives, and fragments, for use in ... [Published Free Patents Online - Jun 24 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Findings on Sepsis Discussed by Investigators at University of Sao Paulo

(NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Bacterial Infections and Mycoses have been published. According to news reporting originating from Sao Paulo, Brazil, by NewsRx correspondents, research stated, ... [Published NewsRX - Jun 20 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

New Cancer Gene Therapy Findings from S. Shahrokhi et al Outlined

(NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating from San Diego, California, by NewsRx correspondents, research stated, ... [Published NewsRX - Jun 20 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Findings from University of Toronto in the Area of Neovascularization Described

(NewsRx) -- By a News Reporter-Staff News Editor at Angiogenesis Weekly -- A new study on Neovascularization is now available. According to news reporting from Toronto, Canada, by NewsRx journalists, research stated, "The aim of this study was to evaluate ... [Published NewsRX - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Popular Crohn's, Colitis Drugs Not Linked to Short-Term Cancer Risk: Study: MedlinePlus

After nearly 4 years of follow-up, people taking the drugs were no more likely to develop cancerWEDNESDAY, June 18, 2014 (HealthDay News) -- A popular class of drugs used to treat inflammatory bowel disease isn't linked to an increase in the short-term ... [Published DailyMe.Com - Jun 19 2014]
Entities: Colitis, Cancer, Risk, Drugs
First reported Jun 17 2014 - Updated Jun 18 2014 - 3 reports

TNF Inhibitors for Treatment of Bowel Disease Not Linked With Increased Risk of Cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 ... [Published Infrosoft - Jun 17 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability ... [Published Free Patents Online - Jun 17 2014]
First reported Jun 14 2014 - Updated Jun 14 2014 - 1 reports

Patient, heal thyself

One morning in May 1998, Kevin Tracey converted a room in his lab at the Feinstein Institute for Medical Research in Manhasset, New York, into a makeshift operating theatre and then prepped his patient - a rat - for surgery.A neurosurgeon, and also Feinstein ... [Published Melbourne Age - Jun 14 2014]


According to the news editors, the research concluded: "ARID-5A is a lineage-specific attenuator of Th17 cell differentiation and may be involved in the pathogenesis of RA."
"FIG. 1A is a chromatogram showing the results of HPLC of the methanol extract, the hexane fraction, the ethyl acetate fraction and the water fraction of Phaseoli angularis Wight;"

More Content

All (182) | News (162) | Reports (0) | Blogs (16) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
A 48-Week Study of Fat Molecular Alterations in... [Published JAIDS - Jul 12 2014]
Which Spices Fight Inflammation? [Published Care2 - Jul 11 2014]
Systematic review with network meta-analysis: t... [Published Alimentary Pharmacology and Therapeutics - Jul 11 2014]
Novartis' secukinumab tops Enbrel in psoriasis [Published PMLive - Jul 11 2014]
Neutrophils Contribute to Excess Serum BAFF Lev... [Published Plosone.org - Jul 10 2014]
Immune Regulation during Chronic Visceral Leish... [Published Plosone.org - Jul 10 2014]
Secukinumab in Plaque Psoriasis — Results of Tw... [Published New England Journal of Medicine - Jul 10 2014]
NIH's Human Placenta Project Is Validation For ... [Published Seeking Alpha - Jul 10 2014]
Investigators at Kazusa DNA Research Institute ... [Published HispanicBusiness.com - Jul 10 2014]
Researchers Submit Patent Application, "Pharmac... [Published HispanicBusiness.com - Jul 09 2014]
Natural compounds to improve thyroid function [Published Natural News - Jul 09 2014]
Gut reaction [Published Drug Discovery News - Jul 09 2014]
TNF antagonists not linked with cancer in Danis... [Published BioPortfolio - Jul 09 2014]
MCP-1 Stimulates MMP-9 Expression via ERK 1/2 a... [Published Sexual Development - Jul 09 2014]
Association between Class III Obesity (BMI of 4... [Published Plosone.org - Jul 08 2014]
TNF-α antagonists not linked with cancer in Dan... [Published PJ Online - Jul 08 2014]
Subcutaneous tocilizumab relieves rheumatoid ar... [Published Orthopedics Today - Jul 08 2014]
Chlamydia-Induced Arthritis: Five Insights and ... [Published Consultant Live - Jul 08 2014]
New agents associated with drug-induced aseptic... [Published Orthopedics Today - Jul 07 2014]
Receptor-interacting protein kinase 3 deficienc... [Published Critical Care - Jul 04 2014]
Methods for diagnosing CNS disorders with fusio... [Published PharmCast - Jul 04 2014]
Diatom-Derived Polyunsaturated Aldehydes Activa... [Published Plosone.org - Jul 03 2014]
UCB and Dermira enter into strategic -3- [Published Scottrade - Jul 03 2014]
Astellas and UCB Japan file application for add... [Published Individual.com - Jul 03 2014]
In Utero Exposure to SSRI May Up Obesity, Diabe... [Published General Medicine eJournal - Jul 02 2014]
Patent Application Titled "Intra-Myocardial Age... [Published HispanicBusiness.com - Jul 02 2014]
Osteochondral fracture with disrupted cortical ... [Published Orthopedics Today - Jul 02 2014]
Vertex Pharmaceuticals : Patent Issued for Thio... [Published 4 Traders - Jul 02 2014]
Non-Invasive Separation of Alcoholic and Non-Al... [Published Plosone.org - Jul 02 2014]
miR-146a Ameliorates Liver Ischemia/Reperfusion... [Published Plosone.org - Jul 02 2014]
1 2 3 4 5 6 7
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Do DMTs delay the onset of secondary progressiv... [Published Multiple Sclerosis Research - Jun 27 2014]
How do we define secondary progressive MS? Is it a rational therapeutic target? #MSBlog #MSResearch "An interesting debate has started within the UK MSology community. Do DMTs that have been shown to reduce relapses, relapse associated disability progression, ...
Physical Activity, Inflammation, and Volume of ... [Published Fight Aging! - Jun 13 2014]
The vast, overwhelming majority of people should undertake regular moderate exercise - just as their physicians no doubt advise, supported by a mountain of evidence for the benefits of exercise. The relationship between physical activity and some specific ...
VC-backed Solstice Biologics hires new presiden... [Published PE Hub Blog - Jun 09 2014]
San Diego-based biotech startup Solstice Biologics , which is backed by venBio and Aeris Capital , has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson ...
[tt] NYT: Michael Behar: Can the Nervous System... [Published TranshumanTech - May 27 2014]
Michael Behar: Can the Nervous System Be Hacked? http://www.nytimes.com/2014/05/25/magazine/can-the-nervous-system-be-hacked.html Michael Behar writes about science and the environment. His work hasappeared in "The Best American Travel Writing" and "The ...
Takeda's Entyvio Wins FDA OK for Severe Colitis [Published MedPageToday.com - medical news plus CME for ph ... - May 20 2014]
(MedPage Today) -- The FDA has approved vedolizumab (Entyvio) for the treatment of moderate-to-severe ulcerative colitis and Crohn's disease in adults who have not fully responded to steroids, immunomodulators, or tumor necrosis factor inhibitors. ...
1 2 3 4
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.